- 文献引用 : 1
|Application ||IHC-P, WB, FC, E|
|Other Names||Vitronectin, VN, S-protein, Serum-spreading factor, V75, Vitronectin V65 subunit, Vitronectin V10 subunit, Somatomedin-B, VTN|
|Target/Specificity||This VTN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 65-93 amino acids from the N-terminal region of human VTN.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||VTN Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.|
|Cellular Location||Secreted, extracellular space.|
Author : Lamar JM1, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO.
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):E2441-50. doi: 10.1073/pnas.1212021109. Epub 2012 Aug 13.
Provided below are standard protocols that you may find useful for product applications.
VTN is a member of the pexin family. This protein is found in serum and tissues and promotes cell adhesion and spreading, inhibits the membrane-damaging effect of the terminal cytolytic complement pathway, and binds to several serpin serine protease inhibitors. The protein is a secreted protein and exists in either a single chain form or a clipped, two chain form held together by a disulfide bond.
Jenne D.E., Stanley K.K.EMBO J. 4:3153-3157(1985) Sigurdardottir O., Wiman B.Biochim. Acta 1208:104-110(1994) Seiffert D., Loskutoff D.J.J. Biol. Chem. 266:2824-2830(1991)